Nucleate Podcast From Genomics to Deal-Making: How Science Becomes a Company | Laurence Reid, Biotech Entrepreneur
13 snips
Mar 24, 2026 Laurence Reid, biotech entrepreneur and former CEO of Decibel and Warp Drive with leadership roles at Alnylam, discusses translating genomics into therapies. He covers moving from bench science to business, the art of durable deal-making, building platform-driven drug discovery, gene therapy for hearing loss, and lessons on leading and fundraising in tough markets.
AI Snips
Chapters
Books
Transcript
Episode notes
Platform Companies Often Become Drug Developers By Acquisition
- Millennium began as a genomics integrator focused on discovering targets across many TAs, then evolved into a drug developer primarily via acquisitions.
- The company later found major commercial success (e.g., Velcade) through bolting on product-focused teams and assets.
Relentless Focus Turned RNAi Into Repeatable Drugs
- Alnylam's success came from relentless focus: pick validated liver targets, solve delivery, then iteratively improve chemistry and formulations.
- That disciplined narrowing turned an uncertain modality into repeatable, high-probability drug programs.
Warp Drive Used Microbial Genomics And Molecular Glue Chemistry
- At Warp Drive Reid helped commercialize platforms mining microbial genomics for natural products and engineering molecular glues to target RAS.
- Warp Drive focused on discovering novel antibiotics and reengineering FKBP/cyclophilin complexes to glue onto RAS, later merging with Revolution Medicines.
